Pure Cartalax 20mg Research peptide

• Product Name: Cartalax
• Alternate Chemical Name: AED (Alanyl-Glutamyl-Aspartic Acid)
• Other Names: AED peptide, T-31
• CAS Number: Not established (no universally verified public CAS number)
• PubChem CID: 87815447
• Molecular Formula: C12H19N3O8
• Molecular Weight: 333.29 g/mol

REFERENCE RECONSTITUTION INFORMATION

Goal: Support connective tissue homeostasis and fibroblast function based on preclinical research. Schedule: Once-daily subcutaneous injections. Cycle Length: 8–12 weeks (optional extension to 16 weeks). Dose Range: 2–5 mg daily. Reconstitution: Add 3.0 mL bacteriostatic water to one 20 mg vial (6.67 mg/mL).

Always follow sterile preparation techniques when handling research peptides.

Educational protocol only; published human clinical dosing remains limited.

General Preparation

• Use a new sterile insulin syringe for each injection. • Rotate injection sites. • Inject at a consistent time each day. • Store refrigerated after reconstitution. • Educational protocol only; published human clinical dosing remains limited.

• Slowly add 3.0 mL bacteriostatic water down the inside wall of the vial. Allow the powder to dissolve naturally and gently swirl until clear. Do not shake vigorously.

CARTALAX (20MG)- RECONSTITUTION TABLES

Reference Handling Information

Reference information for laboratory handling of Cartalax 20mg.

• Schedule: Once-daily subcutaneous injections.
• Cycle Length: 8–12 weeks (optional extension to 16 weeks).
• Dose Range: 2–5 mg daily.

Reference Parameters (Dosing Protocol)

Week / PhaseDaily DoseU-100 UnitsVolumeWeeks 1–22 mg (2,000 mcg)30 units0.30 mLWeeks 3–43 mg (3,000 mcg)45 units0.45 mLWeeks 5–84 mg (4,000 mcg)60 units0.60 mLWeeks 9–125 mg (5,000 mcg)75 units0.75 mLFor laboratory research only.

What is Cartalax?
Cartalax is a synthetic tripeptide bioregulator consisting of Ala-Glu-Asp (AED). It is studied in preclinical research relating to connective tissue, fibroblast activity, cartilage biology and extracellular-matrix homeostasis.

What is Cartalax researched for?
Research has explored Cartalax in areas including connective tissue maintenance, fibroblast function, cartilage biology, cellular maintenance and healthy-ageing research.

How does Cartalax work in research models?
Preclinical research suggests that AED may influence cellular and gene-expression pathways associated with connective-tissue maintenance and extracellular-matrix biology. Findings have included changes in markers such as Ki-67, SIRT-1, SIRT-6, p53, caspase-3 and MMP-9.

What is the amino acid sequence of Cartalax?
Cartalax is composed of the three amino acids Alanine–Glutamic Acid–Aspartic Acid (Ala-Glu-Asp). Its listed molecular formula is C12H19N3O8, with a molecular weight of approximately 333.29 g/mol.

Is Cartalax clinically proven?
Published human clinical data for Cartalax remain limited. Current research is primarily preclinical, so findings from laboratory models should not be interpreted as established clinical outcomes.

How should Cartalax be stored?
Storage requirements can depend on the material's state and laboratory handling conditions. Refer to the product documentation and applicable laboratory protocols for appropriate storage and handling information. Pure Labs lists refrigerated storage following preparation. 

• Amino Acid Sequence: Ala-Glu-Asp (AED)
• Reference Strength: 20 mg
• Appearance: White to off-white lyophilised powder
• Purity Standard: ≥98% (HPLC)
• Category: Khavinson Tripeptide Bioregulator
• Storage: 2–8°C after reconstitution